June 26, 2019 -- 

The gift to UCLA will propel cutting-edge research toward clinical application. Over the past 12 years, the center has achieved critical successes in stem cell gene therapy, stem cell immunotherapy, cell replacement strategies and drug discovery. 

April 09, 2019 -- 

A phase 1 clinical trial to test a novel cancer treatment for advanced-stage lung cancer opens for recruitment. The goal of the trial is to use a combined approach to activate a targeted and precise immune response against lung cancer.

January 17, 2019 -- 

A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells into becoming mature T cells capable of killing tumor cells.

June 28, 2018 -- 

Stem cell gene therapy cures baby with life-threatening immune disorder.

May 24, 2018 -- 

The goal of the trial is to activate a targeted and precise immune response against lung cancer.

April 19, 2018 -- 

With a focus on the delivery of stem cell therapeutics to patients, the symposium highlighted advancements and accomplishments of the ASCC network and shared developments and applications in the field of stem cell therapeutics.

June 01, 2017 -- 

Findings could lead to treatment for osteoporosis and other forms of bone damage or loss.

April 20, 2017 -- 

Findings could help scientists replicate or control the way axons grow more effectively in patients whose nerves have been damaged.

February 09, 2017 -- 

The grant will fund innovative pilot stem cell research projects at UCLA, UCSF and USC.

July 21, 2016 -- 

Stem cell gene therapy approach developed at UCLA holds promise for 60 percent of patients with the deadly disease.

June 15, 2016 -- 

June 10, 2016 -- 

May 20, 2016 -- 

August 30, 2015 -- 

UCLA stem cell scientist and anti-bullying advocate featured on ESPN

August 05, 2015 -- 

Combination therapy targeting cancer stem cells may be more effective against the most common ovarian cancer.

July 23, 2015 -- 

The California Institute for Regenerative Medicine voted unanimously to award UCLA with $7.4 million to lead a phase I/II clinical trial for X-linked chronic granulomatous disease, an immunodeficiency disorder commonly referred to as X-linked CGD. The trial, which will use stem cell gene therapy to correct the genetic defect associated with the disorder, is led by renowned stem cell researcher and UCLA Broad Center of Regenerative Medicine and Stem Cell Research member, Dr. Donald Kohn.

April 07, 2015 -- 

The American Association for Cancer Research (AACR) announced today that Dr. Owen Witte, the founding director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA, will receive the prestigious G.H.A. Clowes Memorial Award. Witte is being recognized for his many contributions to the understanding of human leukemias, immune disorders and the stem cells involved in the formation of epithelial cancers...

March 02, 2015 -- 

Dr. Donald Kohn and colleagues show that a novel stem cell gene therapy method could one day provide a one-time, lasting treatment for sickle cell disease. The stem cell research published today in the journal Blood, outlines a method that corrects the mutated gene that causes sickle cell disease and shows, for the first time, the gene correction method leads to the production of normal red blood cells that do not sickle.

October 23, 2014 -- 

In a first-of-its-kind collaboration, the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and UC Irvine Sue & Bill Gross Stem Cell Research Center received a five year $8M grant from the California Institute of Regenerative Medicine (CIRM), the state’s stem cell agency, to establish a CIRM Alpha Stem Cell Clinic “center of excellence.”

May 29, 2014 -- 

Dr. John Chute has been awarded a Research Leadership Award of $5.1 million from CIRM, the state’s stem cell agency. This is intended to bolster California’s efforts in stem cell research and further its mission to advance novel treatments and cures into medical practice. Dr. Chute’s groundbreaking research focuses on the study of hematopoietic stem cells (HSC, the cells that become blood cells) and how they grow.

May 16, 2014 -- 

UCLA has kicked off its $4.2 billion Centennial Campaign, the largest fundraising effort ever undertaken by a public university. As UCLA counts down to 2019, the 100th anniversary of its founding, the campaign celebrates a century of growth and achievement as a top-tier university. Learn more about giving opportunities for UCLA Broad Stem Cell Research Center and pledge your support today.

May 08, 2014 -- 

The Broad Foundation's $2 million gift to the UCLA Broad Stem Cell Research Center (BSCRC) adds to the 2007 gift of $20 million for which the Center is named. The 2007 gift has supported faculty and research and launched the Innovation Award program, which furthers cutting-edge research at the Center by giving UCLA stem cell scientists "seed funding" for their research projects.

April 14, 2014 -- 

Dr. Owen Witte, director of UCLA’s Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is a 2014 inductee into the American Association for Cancer Research (AACR) Academy. The Academy was created to recognize and honor distinguished scientists whose important research has significantly advanced the fight against cancer.

January 29, 2014 -- 

Recipients of the four Basic Biology V awards from the state stem cell agency, CIRM, included Dr. Lili Yang, Dr. Denis Evseenko, Dr. Thomas Otis and Dr. Ben Novitch, and Dr. Samantha Butler.

August 28, 2013 -- 

Four prominent UCLA stem cell researchers have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.

March 28, 2013 -- 

Dr. Brigitte Gomperts,, a member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research and associate professor of pediatric hematology/oncology, received a Tissue Collection for Disease Modeling grant of over $900,000 from the California Institute of Regenerative Medicine (CIRM).

February 20, 2013 -- 

Five outstanding young professors from UCLA are among 126 scientists and scholars to receive Sloan Research Fellowships from the Alfred P. Sloan Foundation. Two of the five UCLA recipients, Drs. Jason Ernst and Yi Xing, are members of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Center.

March 01, 2012 --  Researchers at UCLA's Jules Stein Eye Institute and colleagues who successfully transplanted specialized retinal cells derived from human embryonic stem cells into the eyes of two legally blind patients report that the transplants appear safe and that both patients have experienced modest improvement in their vision. The patients are part of two separate clinical trials, each of which will eventually include 12 patients. The trials will aim to determine the safety of this particular use of stem cell therapy, as well as the patients' ability to tolerate the treatment. UCLA Newsroom Full Story
More Information on the Clinical Trial at UCLA
Photo: UCLA's Dr. Steven Schwartz performs stem cell transplant. (Source: UCLA Newsroom)

February 10, 2012 -- 

The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA received a $1 million gift today for its annual stem cell symposium that draws top scientists from around the world. The Bloomfield Family Foundation, headed by Margaret “Peggy” Bloomfield of Pacific Palisades, made the gift. Bloomfield is a long-time supporter of the Broad Stem Cell Research Center.

September 21, 2011 -- 

Two BSCRC scientists have received prestigious awards from the National Institutes of Health (NIH) recognizing their leading-edge, innovative research. Researchers Utpal Banerjee, the Irving and Jean Stone Professor and chairman of the Molecular, Cell and Developmental Biology Department and Heather Christofk, an assistant professor of molecular and medical pharmacology, received the NIH Pioneer Award and New Innovator Award, respectively.

May 03, 2011 -- 

Six BSCRC researchers, Drs. Gay Crooks, Shuo Lin, William Lowry, W. Robb MacLellan, Kathrin Plath, and Yi Sun were awarded more than $8 million in grants from the state stem cell agency on May 3 to investigate basic mechanisms underlying stem cell biology and differentiation. The studies supported by these awards will form the foundation for future translational and clinical advances.

January 01, 2011 -- 

Three BSCRC researchers, Dr. Richard Gatti, a professor of pathology and laboratory medicine, Dr. Thomas Carmichael, an associate professor of neurology, and Dr. Martin Martin a professor of pediatrics and gastroenterology, were awarded more than $5.3 million in state grants to develop innovative tools and technologies that will help overcome the technical hurdles in advancing basic, translational and clinical stem cell research.

August 15, 2010 -- 

October 2010 - The state stem cell agency today awarded four grants totaling $12 million to researchers with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA to translate basic science into new and more effective therapies to regenerate bone and treat deadly brain cancers, spinal cord injuries and cornea disorders that result in blindness.

June 01, 2010 -- 

Using stem cells to replace or restore tissues lost to injury or disease represents an area of great promise in regenerative medicine. However, immune rejection of stem cell transplants remains a challenge to translating science from the lab into the clinic. Gay Crooks will use her grant funding to develop “tolerant” T cells, cells that have been engineered to not react against, or reject, transplanted cells.

February 15, 2010 -- 

May 2010 - hESC lines, UCLA 1, 2, and 3, derived by Drs. Amander Clark and Rachel Kim are available for use in federally funded research projects, increasing the diversity of cell lines available for study. UCLA is one of only nine institutions in the world with stem cell lines admitted to the NIH registry.

photo credit: Human Embryonic Stem Cells PLoS Biology via Wikimedia Commons

July 01, 2009 -- 

The STM Program awards young clinician scientists the extraordinary opportunity to pursue translational endeavors that will drive their basic scientific discoveries to clinical application and ultimately impact patient care.

May 01, 2009 -- 

Initial funding for the JCTM comes from a two year, $5 million gift from The Eli and Edythe Broad Foundation to CalTech. The JCTM advances experimental research into clinical applications, including the diagnosis and therapy of diseases such as cancer.

March 09, 2009 -- 

President Obama signs an executive order to lift the restriction imposed by President Bush wherein funding is prohibited for human embryonic stem cell research on cell lines created after August 9, 2001.

February 11, 2008 -- 

Led by Kathrin Plath and William Lowry researchers use genetic alteration to turn back the clock on human skin cells and create cells that are nearly identical to human embryonic stem cells, which have the ability to become every cell type found in the human body. Previously, only two teams of scientists from Kyoto University and the University of Wisconsin-Madison had reported the creation of iPS cells from human cells.

June 06, 2007 -- 

Researchers at the Institute for Stem Cell Biology and Medicine at UCLA were able to take normal tissue cells and reprogram them into cells with the same unlimited properties as embryonic stem cells, the cells that are able to give rise to every cell type found in the body. The implications for disease treatment could be staggering. Reprogramming adult stem cells into embryonic stem cells could generate a potentially limitless source of immune-compatible cells...

June 05, 2007 -- 

The multi-user laboratory space equipped with four tissue culture areas makes possible human embryonic stem cell research that is either not allowed due to current federal funding restrictions or not technically feasible in individual research laboratories.